CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2015 - 2025)

CRISPR Therapeutics AG has disclosed Non-Current Deffered Revenue across 11 years of filings, most recently posting $12.3 million for Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $12.3 million, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2025 was $12.3 million (changed 0.0% YoY), and the FY2024 annual result was $12.3 million, down 12.05% from the prior year.
• Non-Current Deffered Revenue came in at $12.3 million for Q3 2025 at CRISPR Therapeutics AG, roughly flat from $12.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $15.8 million in Q3 2023 to a low of $11.8 million in Q2 2021.
• The 5-year median for Non-Current Deffered Revenue is $12.3 million (2021), against an average of $12.6 million.
• Across the five-year window, Non-Current Deffered Revenue rose 28.4% in 2023 and retreated 22.12% in 2024, its largest moves.
• CRISPR Therapeutics AG's Non-Current Deffered Revenue stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then climbed by 13.71% to $14.0 million in 2023, then retreated by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $12.3 million (Q3 2025), $12.3 million (Q2 2025), and $12.3 million (Q1 2025), per Business Quant data.